Salud

Brasil emite la primera licencia para vender un fármaco basado en cannabis

El tratamiento contra la esclerosis múltiple, un aerosol oral derivado del cannabis, es conocido internacionalmente como Sativex y se venderá en Brasil con el nombre comercial de Mevatyl.

Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.


Brazilian healthcare regulator Anvisa on Monday said it had issued the country's first license for sale of a cannabis-based drug in the country after years of legal wrangling with patients.

The multiple sclerosis treatment, an oral spray derived from marijuana and developed by Britain's GW Pharmaceuticals PLC, is known as Sativex internationally and will be sold in Brazil under the brand name Mevatyl.

The legal status of cannabis-based drugs has been a thorny issue in Brazil for years, with several patients fighting in the courts to circumvent prohibition. Anvisa has loosened some restrictions in the past two years, allowing patients with medical orders to personally import some drugs derived from marijuana.

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Thumbnail: Flickr CC Diego Charlón Sánchez

Apoyado con fondos de

Open Society Foundations Robert Carr Fund

© 2019 International Drug Policy Consortium